

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ADMINISTRATIVE PROCEEDINGS RULINGS

Release No. 6834/ November 3, 2021

ADMINISTRATIVE PROCEEDING

File No. 3-20627

In the Matter of :
:
THE REGISTRATION STATEMENT OF : ORDER
LIFE SCIENCE HOLDINGS, INC. :
:

The Securities and Exchange Commission instituted this proceeding with an Order Instituting Proceedings (OIP) on October 15, 2021, which was served on Respondent Life Science Holdings on October 20, 2021. The proceeding is a stop order proceeding, authorized pursuant to Section 8(d) of the Securities Act of 1933, concerning a Form S-1 Registration Statement filed by Life Science. The OIP ordered Life Science to file an Answer within ten days after service of the OIP and ordered that a hearing commence at 10:00 a.m. on November 2, 2021, via remote means and/or at the Commission’s offices at 100 F Street, N.E., Washington, DC 20549, “to determine whether the allegations of the Division of Enforcement are true; to afford the Respondent with an opportunity to establish any defenses to these allegations; and to determine whether a stop order should issue suspending the effectiveness of the Registration Statement.” OIP at 2-3.

On October 29, 2021, the undersigned ordered that the hearing would be held remotely, via WebEx, noting that instructions for joining the WebEx meeting had been sent to Respondent at its email address, lifesciencelabs@hotmail.com and that any questions could be addressed to the Office of Administrative Law Judges at ALJ@sec.gov or 202-551-6030. *The Registration Statement of Life Science Holdings*, Admin. Proc. Rulings Release No. 6833, 2021 SEC LEXIS 3302.

Respondent did not file an Answer, due on November 1, 2021. The hearing was held as scheduled, on November 2, 2021. Respondent did not appear. At the hearing, the five exhibits that the Division emailed to Respondent on November 1, 2021, were admitted and testimony was taken from Suzanne Hayes, Chief of the Office of Life Sciences, of the Commission’s Division of Corporation Finance (CorpFin), and from Kevin Bugin, Deputy Director of the Office of New Drugs (OND) of the Food and Drug Administration. Ms. Hayes described the processes of CorpFin with regard to Forms S-1 and her communications with Respondent. Mr. Bugin described OND’s evaluation process for new drugs – the steps that must be taken before drugs can be sold and the time frames for each step. A post-hearing briefing schedule was set: the due dates for the Division’s opening filing, Respondent’s opposition, and the Division’s reply are November 23, December 7, and December 14, 2021, respectively.

If Respondent wishes to continue to participate in this proceeding, it should file an Answer to the OIP by November 10, 2021, and respond to the Division's post-hearing filing by the date ordered – December 7, 2021.

IT IS SO ORDERED.

/S/ Carol Fox Foelak
Carol Fox Foelak
Administrative Law Judge